Using deep learning, researchers attempted to classify non-small lung cancer subtypes and predict lung adenocarcinoma mutations from histopathology slides.
An Oregon Health Authority committee issued a draft guidance to not cover NGS testing for solid tumors, which advocacy groups say will limit access to Medicaid beneficiaries.
The firm reported a 69 percent increase in product sales, driven by a 102 percent jump in cartridge sales and jump in research revenues.
The approval includes the use of either tumor tissue or plasma and follows previous approvals with Genentech's Tarceva (erlotinib) and AstraZeneca's Tagrisso (osimertinib).
Physicians can now use the Dako PD-L1 IHC 22C3 pharmDx assay to identify urothelial carcinoma patients who may benefit from the anti-PD1 immunotherapy.
Martin Edelman will investigate whether cancer associated macrophage-like cells can determine whether small or indeterminate lung nodules are cancerous or benign.
The company had no Q2 revenues and continues to advance DetermaVu, its liquid biopsy lung cancer diagnostic test, toward commercialization.
Results of the study, published in JAMA, highlight ongoing and future challenges in translating the promise of comprehensive genomics into clinical benefit.
The Israeli firm recently announced the results of a multicenter study of its Bladder EpiCheck test in addition to netting €2.5 million in EU funding to develop a lung cancer assay.
The company said proceeds will be used for working capital, and may also be used to acquire or invest in complementary businesses or technologies.